This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (12)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Pulmonary Diseases  • Pneumonia  • Gastroenterology  • Gastrointestinal Diseases  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

A Clinical Indication for Rational Prescribing

James C. Gregor, MD

JAMA. 2004;292:2012-2013.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Disorders of the upper gastrointestinal (GI) tract, both symptomatic and asymptomatic, have been ubiquitous in humans throughout the history of medicine. Although important advances, such as the discovery of Helicobacter pylori, have offered curative options for many patients, lifestyle habits and the increasing use of other medication classes, including nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants in western countries, ensure that disorders such as gastroesophageal reflux and NSAID gastropathy will remain prevalent for decades to come.

The development over the last 40 years of potent acid-suppressing agents, first H₂ receptor antagonists (H₂RAs) and subsequently the more potent proton pump inhibitors (PPIs), have led to major improvements in both disease management and diagnosis. Because of their efficacy and impressive safety profile that has far exceeded original expectations, acid-suppressing drugs have consistently been among the most widely prescribed medications worldwide, with almost $13 billion in sales in . . . [Full Text of this Article]

Author Affiliation: Departments of Medicine and Epidemiology & Biostatistics, University of Western Ontario, London, Ontario.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Risk of Community-Acquired Pneumonia and Use of Gastric Acid–Suppressive Drugs
Robert J. F. Laheij, Miriam C. J. M. Sturkenboom, Robert-Jan Hassing, Jeanne Dieleman, Bruno H. C. Stricker, and Jan B. M. J. Jansen
JAMA. 2004;292(16):1955-1960.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Inappropriate prescribing of proton pump inhibitors in primary care
Batuwitage et al.
Postgrad. Med. J. 2007;83:66-68.
ABSTRACT | FULL TEXT  

Systematic review and meta-analysis of randomised controlled trials of gastro-oesophageal reflux interventions for chronic cough associated with gastro-oesophageal reflux
Chang et al.
BMJ 2006;332:11-17.
ABSTRACT | FULL TEXT  

Chronic Cough Due to Gastroesophageal Reflux Disease: ACCP Evidence-Based Clinical Practice Guidelines
Irwin
Chest 2006;129:80S-94S.
ABSTRACT | FULL TEXT  

JournalScan
Gut 2005;54:307-307.
FULL TEXT  

Acid-Suppressive Drugs and Risk for Pneumonia
JWatch Gastroenterology 2004;2004:5-5.
FULL TEXT  

Gastric Acid Suppressants Increase the Risk for Community-Acquired Pneumonia
JWatch Infect. Diseases 2004;2004:3-3.
FULL TEXT  

Gastric Acid Suppression Linked with Risk for Pneumonia
JWatch General 2004;2004:4-4.
FULL TEXT